Pay in 4 interest-free payments of $6.53 Learn more
Ships within 48 hours · Estimated delivery Sep 8 - Sep 13
Patients with cardiovascular risk factors may therefore find a GLP-1RA more appropriate owing to the improvements in cardiometabolic parameters that have been observed with this drug class [10, 37, 46, 47]
None of these are GLP-1-specific, and their effects are individually small
When paired with lifestyle changes like a balanced diet and regular exercise, these alternatives can provide powerful results, helping you achieve sustainable weight loss and improved metabolic health
For breastfeeding individuals, these insights do not predict exact medication response or safety, but may contextualize your metabolic profile and inform provider discussions about timing and alternatives
GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) and the GIP/GLP-1 dual agonist tirzepatide were studied in STEP (semaglutide, weight management, NEJM 2021), SURMOUNT (tirzepatide, weight management, NEJM 2022), and SURMOUNT-OSA (tirzepatide, obstructive sleep apnea, NEJM 2024)
US$ 20.81
US$ 25.53
US$ 28.99
US$ 21.65
US$ 23.70
US$ 27.40
